The determination of unbiased cancer risk estimates in hereditary breast and ovarian cancer syndrome (HBOC) poses several challenges. The article by Katona and colleagues is the first analysis to pro…
Dr. Aditya Bardia presents real-world findings on elacestrant, demonstrating prolonged real-world progression-free survival (rwPFS) in ER+/HER2- advanced breast cancer patients across all clinically relevant subgroups,…
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
Breast cancer survivors who harbor BRCA gene mutation are at elevated risk for second primary cancers, according to study results.These individuals likely would benefit from…
A new study from a postbaccalaureate researcher in Mark Roth’s lab at Fred Hutch Cancer Center, Cameron Suraci, shows that microscopic worms exposed to frigid…
Leonidas Platanias, MD, PhD Director, Lurie Cancer Center In 2024, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University continued to advance our understanding…
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
This clinical insights article is derived from recommendations in Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. This document is based on…
Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.
American Society of Hematology Announces 2025 Scholar Award Recipients
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in…
